D. Boral Capital initiated coverage of Plus Therapeutics (PSTV) with a Buy rating and $9 price target Plus is advancing a unique approach in cancer treatment through its proprietary combination of a powerful diagnostic coupled with a therapeutic radiopharmaceuticals, says the analyst. The company’s lead asset, Rhenium-186, is a radionuclide that holds promise for treating cancers of the central nervous system, particularly Leptomeningeal Metastases and recurrent glioblastoma, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Biotech Alert: Searches spiking for these stocks today
- Plus regains compliance with Nasdaq minimum stockholders’ equity requirement
- Plus Therapeutics announces publication of results on 186Re Obisbemeda
- Plus Therapeutics granted Orphan Drug Designation for Rhenium Obisbemeda
- Plus Therapeutics sees $15M in gross proceeds from private placement